Tedizolid PO + Tedizolid IV
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Cystic Fibrosis
Conditions
Cystic Fibrosis
Trial Timeline
Jul 1, 2015 → Dec 31, 2017
NCT ID
NCT02444234About Tedizolid PO + Tedizolid IV
Tedizolid PO + Tedizolid IV is a approved stage product being developed by Merck for Cystic Fibrosis. The current trial status is completed. This product is registered under clinical trial identifier NCT02444234. Target conditions include Cystic Fibrosis.
What happened to similar drugs?
20 of 20 similar drugs in Cystic Fibrosis were approved
Approved (20) Terminated (7) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02444234 | Approved | Completed |
Competing Products
20 competing products in Cystic Fibrosis